Abstract

BackgroundTo evaluate the safety and efficacy of intravitreal ziv-aflibercept (IVZ) in the management of vitreous hemorrhage (VH) in eyes with previously lasered proliferative diabetic retinopathy (PDR).MethodsIn a prospective multicenter study, previously lasered eyes who had dense VH from PDR underwent intravitreal injection of ziv-aflibercept (IVZ) (1.25 mg aflibercept). Demographic characteristics of the patients, baseline and final logMar visual acuity, number of injections, VH clearance time, and need for vitrectomy were recorded.ResultsTwenty-seven eyes of 21 patients were included in the study. Mean age of study patients was 61.3 ± 14.1 years with mean duration of diabetes mellitus of 22.6 ± 7.8 years. Mean logMAR BCVA at baseline was 1.41 ± 1.26 (Snellen equivalent 20/514) and at the last visit 0.55 ± 0.61 (Snellen equivalent 20/70) with a mean gain of 0.86 EDTRS line (paired student t test = 5.1; p ≤ 0.001). Mean number of IVZ 2.4 ± 1.6 (range 1–6). The mean follow-up time was 11.7 ± 11.1 months (range 1–34). Mean time for visual recovery and/or VH clearance was 5.7 ± 3.3 weeks. Eyes, which required multiple injections, the interval period between injections for recurrent VH was 6.4 ± 5.2 months. No subject required vitrectomy. No ocular or systemic adverse effects were noted.ConclusionsIVZ injections had good short-term safety and efficacy for the therapy of new or recurrent VH in previously lasered eyes with PDR reducing somewhat the need for vitrectomy.Trial registration: NCT02486484

Highlights

  • Panretinal photocoagulation (PRP) is still one of the gold standards for treating proliferative diabetic retinopathy (PDR), yet many patients have an incomplete response with subsequent risk of vitreous hemorrhage (VH) and vision loss [1–5]

  • Spaide and Fisher [1] pioneered the use of vascular endothelial growth factor (VEGF) antagonists in eyes with PDR and VH

  • We evaluated the effect of intravitreal ziv-aflibercept in eyes with VH and PDR following full PRP

Read more

Summary

Introduction

Panretinal photocoagulation (PRP) is still one of the gold standards for treating proliferative diabetic retinopathy (PDR), yet many patients have an incomplete response with subsequent risk of vitreous hemorrhage (VH) and vision loss [1–5]. Spaide and Fisher [1] pioneered the use of vascular endothelial growth factor (VEGF) antagonists in eyes with PDR and VH. Several clinical trials [4–12] have provided evidence that intravitreally administered anti-VEGF drugs (bevacizumab or ranibizumab) may. To evaluate the safety and efficacy of intravitreal ziv-aflibercept (IVZ) in the management of vitreous hemorrhage (VH) in eyes with previously lasered proliferative diabetic retinopathy (PDR)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.